Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Zimmer Biomet Holdings, Inc. (ZBH) President, Americas Gary Craig Campbell reported conversion of 2,368 and 1,218 restricted stock units into common stock on October 1, 2026. The company withheld 932 and 480 common shares to satisfy tax withholding obligations on RSU vesting; both withholding transactions were reported at $88.42 per share. One-third of the 1,218 RSUs vested that day, with the remaining units scheduled to vest one-half on October 1, 2027 and one-half on October 1, 2028.
Zimmer Biomet Holdings, Inc. reports that Brian Matthew Hatcher, President, Recon, SET, CMFT, held 5,988 shares of common stock directly as of October 1, 2026. His direct restricted stock unit holdings were 816, 2,465, 943 and 6,201 units; each unit represents a contingent right to one common share. His employee stock options include 7,035 underlying shares at an exercise price of 117.22, expiring February 18, 2032, and 2,156 shares at 120.04, expiring February 26, 2029.
For Zimmer Biomet Holdings, Inc. (ZBH), Gary Craig Campbell, President, Americas, reported direct holdings on October 1, 2026. They include restricted stock units (RSUs), each a contingent right to receive one common share, and fully vested employee stock options. One RSU lot of 795 vests as 398 shares on February 25, 2027 and 397 on February 25, 2028; other listed RSU lots vest annually over three years beginning October 1, 2026 (3,652 RSUs) and February 20, 2027 (1,292 RSUs).
Zimmer Biomet Holdings, Inc. director Michael J. Farrell acquired 417.363 phantom stock units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. The derivative's conversion or exercise price is stated as 1-for-1, and the units are to be settled in cash in a lump sum within sixty days after Farrell's service as a director ends. His reported resulting holding was 20,073.731 phantom stock units, including 49.652 units accrued on July 31, 2026, under the plan's dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Robert Hagemann acquired 306.0660 phantom stock units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. His reported balance after the acquisition was 33,660.8400 phantom stock units, including 85.331 units accrued on July 31, 2026, under the plan’s dividend reinvestment provision. The units are to be settled in cash in five annual installments, commencing within 60 days after the end of the calendar year in which his director service ends. No Rule 10b5-1 plan is reported.
Zimmer Biomet Holdings, Inc. (ZBH) director Arthur J. Higgins acquired 306.066 Phantom Stock Units on September 30, 2026; they were accrued under the Deferred Compensation Plan for Non-Employee Directors. The units are to be settled in cash in ten annual installments, commencing within 60 days after the end of the calendar year in which his service as a director ends. His reported post-transaction balance was 38,077.496 Phantom Stock Units.
Zimmer Biomet Holdings, Inc. director Louis Shapiro acquired 153.0330 phantom stock units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. His reported balance following the acquisition was 3,865.3110 phantom stock units. The units are to be settled in shares of Company common stock within sixty days after cessation of his service as a director. The conversion or exercise price of the derivative security is 1-for-1.
Zimmer Biomet Holdings, Inc. director Maria Teresa Hilado acquired 375.626 phantom stock units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. Her direct balance after the transaction was 13,392.107 units, including 32.614 units accrued July 31, 2026, under the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Devdatt Kurdikar acquired 173.9010 phantom stock units on September 30, 2026, bringing his reported direct balance to 3,171.3590 units. The units were accrued under the Deferred Compensation Plan for Non-Employee Directors and are to be settled in common stock on a 1-for-1 basis within 60 days after he ceases service as a director. The reported balance includes 7.276 units accrued on July 31, 2026, under the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Sreelakshmi Kolli acquired 173.9010 Phantom Stock Units on September 30, 2026, under the Deferred Compensation Plan for Non-Employee Directors. Her reported holdings after the transaction were 7,033.7570 Phantom Stock Units, including 17.252 units accrued on July 31, 2026, under the plan’s dividend reinvestment provision. The units are to be settled in shares of company common stock within sixty days after cessation of the reporting person’s service as a director.